Short Communications

7 Phosphorylation of ERK1/2 in Dorsal Root Ganglia following Sequential Mustard Oil and Thermal Stimulation of the Rat Hind Paw
Donnerer, J.; Liebmann, I. (Graz)

13 GPR35 is a Target of the Loop Diuretic Drugs Bumetanide and Furosemide
Yang, Y.; Fu, A.; Wu, X.; Reagan, J.D. (South San Francisco, Calif.)

18 Topical Mannitol Reduces Inflammatory Edema in a Rat Model of Arthritis
Cavone, L.; Calosi, L.; Cinci, L.; Moroni, F.; Chiarugi, A. (Florence)

99 Involvement of Target Gene Polymorphisms in 5-Fluorouracil Toxicity: A Case Report
Scalvini, A.; Ferrari, V.; Bodei, S.; Arcangeli, G.; Consoli, E.; Spano, P.; Sigala, S. (Brescia)

111 New Considerations on the Neuromodulatory Role of Thiamine
Hirsch, J.A.; Parrott, J. (New York, N.Y.)

Original Papers

1 Therapeutic Neuroprotective Effects of XQ-1H in a Rat Model of Permanent Focal Cerebral Ischemia
Yang, Q.; Fang, W.; Lv, P.; Geng, X.; Li, Y.; Sha, L. (Nanjing)

22 Inflammation Mobilizes Local Resources to Control Hyperalgesia: The Role of Endogenous Opioid Peptides
Alves, D.P.; da Motta, P.G.; Lima, P.P.; Queiroz-Junior, C.M.; Caliari, M.V.; Pacheco, D.F.; Pacheco, C.F.; Francisch, J.N.; Duarte, I.D.G. (Belo Horizonte)

29 Tachyphylaxis to the Sumatriptan-Induced Contractile Effect in the Human Uterine Artery but Not in Human Cerebral Blood Vessels: Pharmacological Demonstration of the 5-HT₁₈ Receptor Functionality Loss
Silva, S.A.; Ribeiro, C.A.F. (Coimbra)

37 Protective Effect of Amlodipine on Rat Bone Tissue after Orchiectomy

44 Antihypertensive and Cardiorenal Protective Effects of SM-368229, a Novel Mineralocorticoid Receptor Antagonist, in Aldosterone/Salt-Treated Rats

53 Absolute Oral Bioavailability of Almorexant, a Dual Orexin Receptor Antagonist, in Healthy Human Subjects
Hoch, M.; Hoever, P.; Zisowsky, J. (Allschwil); Priestley, A. (Cambridge); Fleet, D. (Salisbury); Dingemanse, J. (Allschwil)

58 Camptothecin Fails to Induce Apoptosis in Tumor Necrosis Factor-Alpha-Treated HaCaT Cells
Sun, J.; Han, J.; Zhu, Q.; Li, Z.; Hu, J. (Shanghai)

64 Differential Treatment Regimen-Related Effects of HU210 on CB₁ and D₂-Like Receptor Functionality in the Rat Basal Ganglia
Nguyen, V.H.; Wang, H. (Lucas Heights, N.S.W.); Verdurand, M. (Lucas Heights, N.S.W./Sydney, N.S.W.); Zavitsanou, K. (Lucas Heights, N.S.W.)

74 Atorvastatin May Delay Cardiac Aging by Upregulating Peroxisome Proliferator-Activated Receptors in Rats
Han, L.; Li, M.; Liu, Y.; Han, C.; Ye, P. (Beijing)

(Continued on inside front cover)
83 Evaluation of Antidepressant-Like Activity of Novel Water-Soluble Curcumin Formulations and St. John’s Wort in Behavioral Paradigms of Despair
Kulkarni, S.K.; Akula, K.K. (Chandigarh); Deshpande, J. (Thane)

91 Aloe Emodin Induces G2/M Cell Cycle Arrest and Apoptosis via Activation of Caspase-6 in Human Colon Cancer Cells
Suboj, P.; Babykutty, S.; Srinivas, P.; Gopala, S. (Thiruvananthapuram)

105 The Influence of MDR1 G2677T/A Genetic Polymorphisms on the Pharmacokinetics of Repaglinide in Healthy Chinese Volunteers
Xiang, Q.; Cui, Y.M.; Zhao, X.; Yan, L.; Zhou, Y. (Beijing)

Comment

103 Hemoptysis and Pulmonary Edema in a Scuba Diver Using Diclofenac
Van Renterghem, D.; Depuydt, C. (Brugge)
Guidelines for Authors

Submission
The journal publishes articles dealing with all aspects of experimental and clinical pharmacology. Papers dealing with mechanistic aspects at a molecular level are particularly encouraged. They can be full articles as well as short communications of investigative findings. Reviews, comments and perspective notes on timely topics are specifically welcome. We consider investigations dealing with biological extracts or with phytopharmacological preparations as outside the scope of our journal. Only papers written in English are considered and should be submitted using the online submission website at:

www.karger.com/pha

or sent as e-mail attachment (the preferred word-processing package is MS-Word) to the Editorial Office:

pha@karger.ch

Prof. J. Donnnerer
S. Karger AG
Editorial Office 'Pharmacology'
PO. Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1356
Fax +41 61 306 1434

Conditions
All manuscripts are subject to editorial review. Manuscripts which do not properly consider ethical issues for humans or animals will not be accepted for publication. In the 'Methods' section, it is recommended to mention the approval given by the responsible authorities. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of 'Pharmacology' and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflicts of Interest
Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Ethics
Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute's committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Arrangement
Title page: The first page of each paper should indicate the title, the authors' names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract of up to 10 lines.

Drug names: Authors are requested to use International non-proprietary names definitely recommended or, if no final recommendation has been made, proposed by the World Health Organisation (WHO). The use of laboratory code numbers necessitates prior explanation by chemical name or structural formula.

Footnotes: Avoid footnotes.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 225 mm) or provide strip maps. Each illustration must be labeled with its number and the first author's name. The final resolution for b/w half-tone and color illustrations must be 300 dpi after scaling. Line drawings require 800–1,200 dpi. Figures from a page are folded in a document file but submitted separately for detailed instructions, see http://www.karger.com/pha.

Color illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page.

References
In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as 'unpublished data' and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastectomy patients. Int Arch Allergy Immunol 2006;140:489-495.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable formats and sizes are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author's Choice
Karger's Author's Choice service broadens the reach of your article and gives all authors worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author's Choice service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH's Public Access Policy are available at http://publicaccess.nih.gov/policy.htm

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger's Author's Choice service, however, are also permitted to archive the final, published version of their article, which includes copying, editing and design improvements as well as citation links.

Page Charges
There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.–. The allotted size of a paper is equal to approx. 14 manuscript pages (including tables, illustrations and references).

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer's errors are charged to the author.

Reprints
Order form and price list is sent with the pdf proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
Recommended Abbreviations and Symbols

Abbreviations and Terminology

The IUB Recommendations should be followed, as far as possible, for the nomenclature of the enzymes (Enzyme Nomenclature, Academic Press, New York, 1978). Thus the enzymes must be identified by their corresponding Enzyme Commission name and number. Recommended trivial names are accepted. Non-standard abbreviations should be explained before use. For the expression of catalytic activities the IFCC Methods for the measurement of catalytic concentration of enzymes (e.g. Clin Chim Acta 1979;98:163F–174F) should be followed.

The catalytic activity of an enzyme can be either reported in nkat or mkat (1 kat, KATAL = 1 mol.s–1) or as µmol.min–1 under stated conditions (temperature, pH, kind of buffer, ionic strength, etc.). Catalytic activity concentration should be given as nkat.l–1 or µkat.l–1, or as µmol.min–1.l–1 or, when referring the activity per mass of protein or another reference basis, by an appropriate mass unit (kg, g, mg). Enzyme assays in tissues, that are considered to measure (relative) concentrations, can be confirmed by other assays only in relation to some standard. Authors are therefore encouraged to give, as part of the method, the activity in some generally available standard or in some common reference tissue such as adult male rat liver.

For the other quantities the Recommendations of the Section of Clinical Chemistry of the International Union of Pure and Applied Chemistry (IUPAC) and of the International Federation of Clinical Chemistry (IFCC) should be considered (Quantities and Units in Clinical Chemistry. Pure Appl Chem 1974;37:517,547). The abbreviations and most common units are listed as follows:

### Standard Abbreviations of Chemical Compound

<table>
<thead>
<tr>
<th>Standard Abbreviations of Chemical Compound (which do not need to be explained)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMP, ADP, ATP</td>
</tr>
<tr>
<td>CoA</td>
</tr>
<tr>
<td>DNA</td>
</tr>
<tr>
<td>EDTA</td>
</tr>
<tr>
<td>EGTA</td>
</tr>
<tr>
<td>FAD</td>
</tr>
<tr>
<td>FMN</td>
</tr>
<tr>
<td>GABA</td>
</tr>
<tr>
<td>HEPES</td>
</tr>
<tr>
<td>5-HT</td>
</tr>
<tr>
<td>NAD (NADH)</td>
</tr>
<tr>
<td>NADP (NADPH)</td>
</tr>
<tr>
<td>P,</td>
</tr>
<tr>
<td>PP,</td>
</tr>
<tr>
<td>RNA</td>
</tr>
<tr>
<td>UMP, UDP, UTP</td>
</tr>
<tr>
<td>SDS</td>
</tr>
</tbody>
</table>

### Recommended Abbreviations and Symbols

<table>
<thead>
<tr>
<th>Common units</th>
<th>Recommended</th>
<th>Not recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Length</td>
<td>m</td>
<td>cm, mm, µm, nm</td>
</tr>
<tr>
<td></td>
<td>µ, u</td>
<td>μ, mu</td>
</tr>
<tr>
<td></td>
<td>(in, ft, yd, A)</td>
<td></td>
</tr>
<tr>
<td>Area</td>
<td>m²</td>
<td>cm², mm², µm²</td>
</tr>
<tr>
<td></td>
<td>µ²</td>
<td>(sq. in, in²)</td>
</tr>
<tr>
<td>Volume</td>
<td>m³</td>
<td>l, dm³, ml, µl</td>
</tr>
<tr>
<td></td>
<td>mm³</td>
<td>l, cm³, µl</td>
</tr>
<tr>
<td>Mass</td>
<td>kg</td>
<td>Kg</td>
</tr>
<tr>
<td></td>
<td>g</td>
<td>gr, gm, gms, GRM</td>
</tr>
<tr>
<td></td>
<td>mg</td>
<td>mgm, mgms</td>
</tr>
<tr>
<td></td>
<td>µg</td>
<td>g, µg</td>
</tr>
<tr>
<td></td>
<td>ng</td>
<td>ng</td>
</tr>
<tr>
<td></td>
<td>µg</td>
<td>(oz, lb, etc.)</td>
</tr>
<tr>
<td></td>
<td>µg</td>
<td>µg</td>
</tr>
<tr>
<td>Molar concentration</td>
<td>mol/l</td>
<td>mmol/l</td>
</tr>
<tr>
<td></td>
<td>µmol/l</td>
<td>nmol/l</td>
</tr>
<tr>
<td></td>
<td>M</td>
<td>µM</td>
</tr>
<tr>
<td></td>
<td>µM</td>
<td>µM</td>
</tr>
<tr>
<td>Particle concentration</td>
<td>10⁻³ l, 10⁻³ l⁻¹</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1/µl⁻¹</td>
<td>10⁻³ l⁻¹</td>
</tr>
<tr>
<td>Temperature</td>
<td>K, °C</td>
<td>(thermodynamic temperature, Celsius temperature)</td>
</tr>
<tr>
<td>Time</td>
<td>a</td>
<td>yr</td>
</tr>
<tr>
<td></td>
<td>d</td>
<td>da</td>
</tr>
<tr>
<td></td>
<td>h</td>
<td>hs</td>
</tr>
<tr>
<td></td>
<td>min</td>
<td>min.</td>
</tr>
<tr>
<td></td>
<td>s</td>
<td>sec</td>
</tr>
<tr>
<td>(Mass) Density</td>
<td>kg/l</td>
<td></td>
</tr>
</tbody>
</table>
Contents

See the journal website for contents
SMi present their inaugural...

ADC Summit
Innovation, Development & Utility

Wednesday 23rd and Thursday 24th May 2012, Copthorne Tara Hotel, London

KEY TOPICS:
- Application of antibodies as targeting agents
- Novel linker strategies
- Developing tumor targeting antibody drug conjugates
- Clinical tests of antibody-maytansinoid conjugates
- Antibody fragments and alternative scaffold-based ADCs
- Innovations in ADC delivery

KEY SPEAKERS INCLUDE:
- John Flygare, Senior Scientist, Genentech
- Michel Awwad, Senior Director, Pfizer
- John Lambert, Chief Scientific Officer, Immunogen
- James Smothers, Director and Preclinical Research Head, GSK
- Lutz Jermutus, Global Head, Technology, Medimmune
- Vincent de Groot, Vice President, Antibody Drug Conjugates, Synthon
- Kathy Kozak, Scientist, Biochemical and Cellular Pharmacology, Genentech
- Wen Jin Wu, Principal Investigator, Division of Monoclonal Antibodies, FDA

PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS
Tuesday 22nd May 2012, Copthorne Tara Hotel, London

A: Novel Linker Strategies
   Workshop Leader: Guilio Casi, Research Scientist, Philochem
   9.30am – 12.30pm

B: Regulatory Expectation for Antibody Drug Conjugates:
   Successful Transition from the Bench to the Clinic
   Workshop Leaders: Sohail Chohan, Associate Director, CMC Regulatory, ERA Consulting
   1.00pm-5.30pm

Visit our website here:
www.smi-online.co.uk/adcsummit12.asp
Alternatively or Fateja Begum on tel: +44 (0) 20 7827 6184 or
email: fbegum@smi-online.co.uk
SMi present their 15th annual conference on...

Generics, Supergenerics and Patent Strategies
Monday 14th & Tuesday 15th May 2012, The Copthorne Tara Hotel, London

KEY SPEAKERS INCLUDE:
Richard Dicicco
Chairman
Harvest Moon Pharmaceuticals

Rex Clements
Country Head
Sandoz

Douglas Andrews
CEO
Stravencon

Paul Csiszár
Director
European Commission

Alan Sheppard
Global Head Generics, Thought Leadership
IMS Health

Ewan Livesey
Senior Vice President Corporate Development: Europe
Country Manager: Switzerland
Lupin Holdings

KEY REASONS TO ATTEND:
• Hear the latest on the prospects for the future of the generics industry
• Learn about recent approaches to patent strategies and changes in the legal landscape for generics
• See why and how the boundaries between innovator and generic companies are becoming ever more blurred
• Study recent strategies in business development and licensing
• Network with senior representatives from a range of multi-national companies

PLUS TWO HALF-DAY POST CONFERENCE WORKSHOPS
Wednesday 16th May 2012,
The Copthorne Tara Hotel, London

Innovative Regulatory Strategies for Generics
Workshop leader: Maureen Graham, Managing Director & Regulatory Affairs Consultant, Diamond BioPharm Ltd
9.00am-12.30pm

Developing patent litigation strategies for EU markets
Workshop Leader: Duncan Curley, Director, Innovate Legal
1.30pm-5.30pm

To register visit
www.smi-online.co.uk/generic-pharma11.asp
Alternatively contact Ninica Hussain on tel: +44 (0) 20 7827 6115
or email: nhussain@smi-online.co.uk
The Zing Nanotechnology 2012 Conference serves as an opportunity for nanotechnologists and well recognized authorities, especially of medicine and dentistry from across the region and around the world. This landmark conference will provide a superb platform for conversation, collaboration, and networking among pharmaceutical scientists, clinical researchers, physicians, therapists and industrial leaders to discuss the important international breakthrough developments in drug discovery, drug development, drug delivery, drug therapy and people from commerce to share their thoughts. The conference will address the topics of novel issues concentrating more on recent advances, difficulties, and breakthroughs in the field of drug delivery, sensors, imaging, diagnostics and nanotoxicology with nanoscale systems.

31st October - 3rd November 2012
Occidental Grand Xcaret Hotel, Riviera Maya, Mexico.

Please see website for full conference details.
Nano 2012

Monday, April 23, 8 a.m. – 5 p.m.
The Center for Biotechnology and Interdisciplinary Studies
Rensselaer Polytechnic Institute, Troy, NY

Nano 2012 is an international multi-disciplinary conference which explores commercialization opportunities of nanotechnology, medicine, pharma, biotechnology, and related science and engineering fields. While exploring innovative research and development efforts that are underway globally, presenters at the conference will highlight the urgent need for vigilance with regard to ‘nanotoxicity.’ Ethical, business, FDA and patent law issues will also be examined to ensure a fruitful future for the science of manipulating and building at the molecular level.

The 10th Anniversary conference is exploring the global opportunities in nanobiotechnology and related science and engineering fields

2012 Organizing Committee

Kathy Kinsey • Rensselaer Polytechnic Institute (Troy, NY)
Ellen Johnston • Rensselaer Polytechnic Institute (Troy, NY)
Susan Gilbert • Rensselaer Polytechnic Institute (Troy, NY)
Chid Iyer • Sughrue Mion (Washington, DC)
Stephen Maebius • Foley Lardner (Washington, DC)
Rutledge Ellis-Behnke • University of Heidelberg (Germany) and MIT (Cambridge, MA)
S. R. Bawa • Bawa Biotech LLC (Schenectady, NY)
Annette I. Kahler • Heslin Rothenberg Farley & Mesiti P.C. (Albany NY)
Jagat Kanwar • Deakin University (Australia)
Drew Harris • Attorney General’s Office (Austin, TX)
Ratnesh N. Mehra • Philadelphia College of Osteopathic Medicine (Philadelphia, PA)
Raj Bawa • Bawa Biotech LLC (Ashburn, VA); Rensselaer Polytechnic Institute (Troy, NY) Chair

For more information please contact Kathy Kinsey in the Office of Alumni Relations at kinsek@rpi.edu or (518) 276-2832, or the conference chair, Dr. Raj Bawa ’90 at bawa@bawabiotech.com or (703) 582-1745.
The search for innovative and effective drugs begins here

Pharmacology
International Journal of Experimental and Clinical Pharmacology

Editors
J. Donnerer, Graz
M.L. Billingsley, Hershey, Pa.
M. Maeyama, Matsuyama

Pharmacology is an international forum to present and discuss current perspectives in drug research. The journal communicates research in basic and clinical pharmacology and related fields. It covers biochemical pharmacology, molecular pharmacology, immunopharmacology, drug metabolism, pharmacogenetics, analytical toxicology, neuropsychopharmacology, pharmacokinetics and clinical pharmacology. In addition to original papers and short communications of investigations, the journal contains reviews, comments and perspective notes; research communications of novel therapeutic agents are encouraged.

Selected contributions
- Proteomic Approach to the Study of Statin Pleiotropy in Kidney Transplant Patients: Pérez, V.; Navarro-Muñez, M. (Barcelona); Mas, S. (Madrid); Bayés, B.; Pastor, M.C.; Martinez-Cáceres, E.; Lauzurica, R. (Barcelona); Egido, J. (Madrid); Romero, R. (Barcelona)
- A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes: Fakhoury, W.K.H.; LeReun, C.; Wright, D. (London)
- Personalized Prognosis and Diagnosis of Type 2 Diabetes - Vision or Fiction?: Müller, G. (Munich)
- CRTH2 and D-Type Prostanoid Receptor Antagonists as Novel Therapeutic Agents for Inflammatory Diseases: Schuligoi, R.; Sturm, E.; Luschnic, P.; Konya, V.; Philippe, S.; Sedej, M.; Waldotho, M.; Peskar, B.A.; Heinemann, A. (Graz)
- Cannabinoids Inhibit Cellular Respiration of Human Oral Cancer Cells: Whyte, D.A. (Syracuse, N.Y.); Al-Hammadi, S.; Balhaj, G. (Al Ain); Brown, O.M. (Syracuse, N.Y.); Penefsky, H.S. (New Jersey, N.J.); Soudi, A.-K. (Al Ain)

More information at www.karger.com/pha
- Pay-per-View and Subscriber Access to Full Text
- Full Table of Contents
- Full Editorial Board
- Free Abstracts and Selected Articles
- Online Sample Issue
- Submission/Guidelines for Authors
- Subscription Details
- Free Alert Service
- Online Library Recommendation

Pharmacology
2012: Volumes 89, 90
6 issues per volume
Language: English
ISSN 0031–7012 (print)
ISSN 1423–0313 (online)

Listed in bibliographic services, including Current Contents®, MEDLINE, Biological Abstracts, EMBASE/Excerpta Medica, Chemical Abstracts
New Trends in Allergy and Atopic Eczema

Editors
Johannes Ring
Ulf Darsow
Heidrun Behrendt

Contents
Preface
Ring, J.; Darsow, U.; Behrendt, H.

Allergy and Environment:
Determinants of Allergy Development
Allergy in Evolution: Platts-Mills, T.A.E.
Climate Change, Environment and Allergy: Behrendt, H.; Ring, J.
Molecular Genetics of Atopic Eczema: Ring, J.; Möhrenschlager, M.; Weidinger, S.

Pathogenesis of the Deviated Immune Response
Mechanisms of Immune Tolerance to Allergens: Fujita, H.; Meyer, N.; Akdis, M.; Akdis, C.A.
Th17 and Th22 in Skin Allergy: Cavani, A.; Pennino, D.; Eyerich, K.

IL-25 Induces Both Inflammation and Skin Barrier Dysfunction in Atopic Dermatitis: Deleuran, M.; Hvid, M.; Kemp, K.; Christensen, G.B.; Deleuran, B.; Vestergaard, C.
Angiogenesis, Lymphangiogenesis and Atopic Dermatitis: Genovese, A.; Detoraki, A.; Granato, F.; Galdiero, M.R.; Spadaro, G.; Marone, G.
What Can Dogs Bring to Atopic Dermatitis Research? Olivry, T.
Can Microbial Superantigens Influence Atopic Dermatitis Flares? Alomar, A.
Inflammation-Induced Alterations in the Skin Barrier Function: Implications in Atopic Dermatitis: Vestergaard, C.; Hvid, M.; Johansen, C.; Kemp, K.; Deleuran, B.; Deleuran, M.

Clinical Aspects
Itch and Eczema: Darsow, U.; Pfab, F.; Valet, M.; Tölle, T.R.; Ring, J.
Eczema Herpeticum: Wollenberg, A.
Bone Mineral Density in Patients with Atopic Dermatitis: Hoeck, I.; van Velsen, S.; de Bruin-Weller, M.; Bruijnzeel-Koomen, C.


Therapy and Management
New Strategies for Dealing with Staphylococcus aureus Colonization and the Emerging Methicillin-Resistant Staphylococcus aureus Epidemic in Atopic Dermatitis: Boguniewicz, M.
Anti-IL-4 as a New Strategy in Allergy: Schmidt-Weber, C.B.
Latest Approaches to Treating Atopic Dermatitis: Paller, A.S.

Author Index
Subject Index